BRIEF-Telix Pharmaceuticals Sees OPEX To Be 36% Of Revenue In H1 2025 (Unaudited)

Like
1
Favorite

BRIEF-Telix Pharmaceuticals Sees OPEX To Be 36% Of Revenue In H1 2025 (Unaudited)

Reuters08-05

BRIEF-<a href="https://laohu8.com/S/TLX.AU">Telix Pharmaceuticals</a> Sees OPEX To Be 36% Of Revenue In H1 2025 (Unaudited)

Aug 5 (Reuters) - Telix Pharmaceuticals Ltd TLX.AX:

OPEX EXPECTED TO BE 36% OF REVENUE IN H1 2025 (UNAUDITED)

Further company coverage: TLX.AX

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（1）

Anton 89
·08-05
📌 Market Note: Telix's 36% Expense Ratio Is a Positive Surprise — Not a Red Flag Posted: 5 August 2025 Author: Anton89 This afternoon, Telix Pharmaceuticals (ASX: TLX) announced an unaudited operating expense ratio of 36% of revenue for H1 2025, triggering a sharp share price decline of up to –21%, before recovering slightly to –15% at the time of writing. However, based on a closer look at industry norms and Telix’s financial history, this 36% figure represents a substantial improvement in operational efficiency, not a deterioration — and the market may have misread it entirely. 🧾 What Telix Reported Operating expenses (OpEx) expected to be 36% of revenue for the first half of 2025 (unaudited). This compares to ~93% OpEx-to-revenue in FY 2024 — a major improvement. 📊 What This Means (And
Reply
1
Report

Most Discussed

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2557353544?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-05 09:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557353544","market":"nz","top_or_hot":-1,"title":"BRIEF-Telix Pharmaceuticals Sees OPEX To Be 36% Of Revenue In H1 2025 (Unaudited)","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a> Sees OPEX To Be 36% Of Revenue In H1 2025 (Unaudited)</title></head><body><p><span>Aug 5 (Reuters)</span><span> - </span>Telix Pharmaceuticals Ltd <span>TLX.AX</span>:</p><ul><li><p>OPEX EXPECTED TO BE 36% OF REVENUE IN H1 2025 (UNAUDITED)</p></li></ul><p>Further company coverage: <span>TLX.AX</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Telix Pharmaceuticals Sees OPEX To Be 36% Of Revenue In H1 2025 (Unaudited)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Telix Pharmaceuticals Sees OPEX To Be 36% Of Revenue In H1 2025 (Unaudited)\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-05 09:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a> Sees OPEX To Be 36% Of Revenue In H1 2025 (Unaudited)</title></head><body><p><span>Aug 5 (Reuters)</span><span> - </span>Telix Pharmaceuticals Ltd <span>TLX.AX</span>:</p><ul><li><p>OPEX EXPECTED TO BE 36% OF REVENUE IN H1 2025 (UNAUDITED)</p></li></ul><p>Further company coverage: <span>TLX.AX</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TLX.AU","symbol_name":"TELIX PHARMACEUTICALS LTD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250805:nFWN3TW1GZ:1","article_id":"2557353544","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557353544","pubTimestamp":1754357357,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Telix Pharmaceuticals Sees OPEX To Be 36% Of Revenue In H1 2025 (Unaudited)Aug 5 (Reuters) - Telix Pharmaceuticals Ltd TLX.AX:OPEX EXPECTED TO BE 36% OF REVENUE IN H1 2025 (UNAUDITED)Further company coverage: TLX.AX ((Reuters.Briefs@thomsonreuters.com;))","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TLX.AU":"TELIX PHARMACEUTICALS LTD"},"translate_title":"简介-Telix Pharmaceuticals预计2025年上半年运营支出将占收入的36%（未经审计）","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLX.AU":0.9},"content_text":"BRIEF-Telix Pharmaceuticals Sees OPEX To Be 36% Of Revenue In H1 2025 (Unaudited)Aug 5 (Reuters) - Telix Pharmaceuticals Ltd TLX.AX:OPEX EXPECTED TO BE 36% OF REVENUE IN H1 2025 (UNAUDITED)Further company coverage: TLX.AX ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":464230035660824,"gmtCreate":1754362297799,"gmtModify":1754365462316,"author":{"id":"4183091609998932","authorId":"4183091609998932","name":"Anton 89","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":12,"crmLevelSwitch":0,"idStr":"4183091609998932","authorIdStr":"4183091609998932"},"htmlText":"📌 Market Note: Telix's 36% Expense Ratio Is a Positive Surprise — Not a Red Flag Posted: 5 August 2025 Author: Anton89 This afternoon, Telix Pharmaceuticals (ASX: TLX) announced an unaudited operating expense ratio of 36% of revenue for H1 2025, triggering a sharp share price decline of up to –21%, before recovering slightly to –15% at the time of writing. However, based on a closer look at industry norms and Telix’s financial history, this 36% figure represents a substantial improvement in operational efficiency, not a deterioration — and the market may have misread it entirely. 🧾 What Telix Reported Operating expenses (OpEx) expected to be 36% of revenue for the first half of 2025 (unaudited). This compares to ~93% OpEx-to-revenue in FY 2024 — a major improvement. 📊 What This Means (And","listText":"📌 Market Note: Telix's 36% Expense Ratio Is a Positive Surprise — Not a Red Flag Posted: 5 August 2025 Author: Anton89 This afternoon, Telix Pharmaceuticals (ASX: TLX) announced an unaudited operating expense ratio of 36% of revenue for H1 2025, triggering a sharp share price decline of up to –21%, before recovering slightly to –15% at the time of writing. However, based on a closer look at industry norms and Telix’s financial history, this 36% figure represents a substantial improvement in operational efficiency, not a deterioration — and the market may have misread it entirely. 🧾 What Telix Reported Operating expenses (OpEx) expected to be 36% of revenue for the first half of 2025 (unaudited). This compares to ~93% OpEx-to-revenue in FY 2024 — a major improvement. 📊 What This Means (And","text":"📌 Market Note: Telix's 36% Expense Ratio Is a Positive Surprise — Not a Red Flag Posted: 5 August 2025 Author: Anton89 This afternoon, Telix Pharmaceuticals (ASX: TLX) announced an unaudited operating expense ratio of 36% of revenue for H1 2025, triggering a sharp share price decline of up to –21%, before recovering slightly to –15% at the time of writing. However, based on a closer look at industry norms and Telix’s financial history, this 36% figure represents a substantial improvement in operational efficiency, not a deterioration — and the market may have misread it entirely. 🧾 What Telix Reported Operating expenses (OpEx) expected to be 36% of revenue for the first half of 2025 (unaudited). This compares to ~93% OpEx-to-revenue in FY 2024 — a major improvement. 📊 What This Means (And","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/464230035660824","repostId":2557353544,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}